Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

CEO Paul Hudson says that the French major will continue to progress early-stage cancer projects despite jettisoning some oncology programs in favor of reallocating much of its research budget to immunology.